Figure 1.
Prognostic significance and immunotherapy efficacy prediction of KCTD9. (A). Cox regression analysis of KCTD9 on OS for pan-cancer was depicted via forest diagram. (B-C) The correlation between KCTD9 expression and TMB or MSI. (D) A comparison of KCTD9 mRNA expression levels between normal and colon tumor patients. (E) CD8-positive α-β T-cell activation pathway was enriched in KCTD9-related COAD in the GO-BP category; NES, normalized enrichment score.
